Release Date: 21/11/13 11:35 Summary: CEO's Presentation at 2013 Annual General Meeting Price Sensitive: No Download Document 2.6MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%